RenovoRx, Inc.
RNXTNASDAQHealthcare● Active
$0.90
+$0.02(+1.91%)
Market Cap$33595562
P/E Ratio—
52W High$1.45
52W Low$0.701
RenovoRx, Inc. (RNXT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RNXT · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.08
Est. -$0.08 · +0.0%
Revenue
$0.00B
Est. $0.00B · +19.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▲ Beat Revenue🔥 11-Quarter EPS Beat Streak
RNXT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $6.21B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$6.21B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.08 | — | — | — | $0.00B | — |
| — Q2 FY2026 | May 14, 2026 | -$0.08 | -$0.08 | +0.0% | $0.00B | $0.00B | +19.9% |
| — Q1 FY2026 | Mar 30, 2026 | -$0.08 | -$0.08 | +0.0% | $0.00B | $0.00B | -43.3% |
| — Q4 FY2025 | Nov 13, 2025 | -$0.08 | -$0.08 | +0.0% | $0.00B | $0.00B | -34.4% |
| — Q3 FY2025 | Aug 14, 2025 | -$0.08 | -$0.08 | +0.0% | $0.00B | $0.00B | +38.8% |
| — Q2 FY2025 | May 15, 2025 | -$0.08 | -$0.08 | +0.0% | $0.00B | $0.00B | +7.5% |
| ▲ Q1 FY2025 | Mar 31, 2025 | -$0.13 | -$0.12 | +7.7% | $0.00B | $0.00B | -74.3% |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$0.12 | -$0.10 | +16.7% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.08
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026
EPS Actual
-$0.08
EPS Est.
-$0.08
EPS Surpr.
+0.0%
Revenue
$0.00B
Q1 FY2026
Mar 30, 2026
EPS Actual
-$0.08
EPS Est.
-$0.08
EPS Surpr.
+0.0%
Revenue
$0.00B
Q4 FY2025
Nov 13, 2025
EPS Actual
-$0.08
EPS Est.
-$0.08
EPS Surpr.
+0.0%
Revenue
$0.00B
Q3 FY2025
Aug 14, 2025
EPS Actual
-$0.08
EPS Est.
-$0.08
EPS Surpr.
+0.0%
Revenue
$0.00B
Q2 FY2025
May 15, 2025
EPS Actual
-$0.08
EPS Est.
-$0.08
EPS Surpr.
+0.0%
Revenue
$0.00B
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
-$0.12
EPS Est.
-$0.13
EPS Surpr.
+7.7%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.10
EPS Est.
-$0.12
EPS Surpr.
+16.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.03 | $-0.02 | $-0.01 | 1 |
| Q3 FY2027 | $-0.04 | $-0.03 | $-0.02 | 1 |
| Q2 FY2027 | $-0.06 | $-0.04 | $-0.03 | 1 |
| Q1 FY2027 | $-0.07 | $-0.05 | $-0.03 | 1 |
| Q4 FY2026 | $-0.09 | $-0.07 | $-0.04 | 1 |
| Q3 FY2026 | $-0.06 | $-0.05 | $-0.04 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 14, 2026 | +0.0% | $0.85 | $0.86 | +0.75% |
| ▲ Q1 FY2026 | Mar 30, 2026 | +0.0% | $1.13 | $1.07 | -5.31% |
| ▲ Q4 FY2025 | Nov 13, 2025 | +0.0% | $1.00 | $0.97 | -2.56% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +0.0% | $1.22 | $1.24 | +1.64% |
| ▲ Q2 FY2025 | May 15, 2025 | +0.0% | $1.05 | $1.11 | +5.71% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +7.7% | $1.00 | $0.99 | -1.00% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +16.7% | $1.10 | $1.09 | -0.91% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +0.0% | $1.14 | $1.16 | +1.75% |
Q2 FY2026+0.75%
Report Date
May 14, 2026
EPS Beat/Miss
+0.0%
Price Before
$0.85
Price After
$0.86
Q1 FY2026-5.31%
Report Date
Mar 30, 2026
EPS Beat/Miss
+0.0%
Price Before
$1.13
Price After
$1.07
Q4 FY2025-2.56%
Report Date
Nov 13, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.00
Price After
$0.97
Q3 FY2025+1.64%
Report Date
Aug 14, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.22
Price After
$1.24
Q2 FY2025+5.71%
Report Date
May 15, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.05
Price After
$1.11
Q1 FY2025-1.00%
Report Date
Mar 31, 2025
EPS Beat/Miss
+7.7%
Price Before
$1.00
Price After
$0.99
Q4 FY2024-0.91%
Report Date
Nov 13, 2024
EPS Beat/Miss
+16.7%
Price Before
$1.10
Price After
$1.09
Q3 FY2024+1.75%
Report Date
Aug 13, 2024
EPS Beat/Miss
+0.0%
Price Before
$1.14
Price After
$1.16
Avg Beat Reaction+0.01%
Beat Rate8 / 8 quarters
Largest Move+5.71% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RNXT ends December
RenovoRx, Inc. (RNXT) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.08 (in line with the analyst consensus of $-0.08). RNXT has beaten EPS estimates for 11 consecutive quarters. The next RNXT earnings date is expected around September 1, 2026.
Each quarter, investors track RNXT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RNXT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RNXT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RNXT earnings · 4 questionsRenovoRx, Inc.'s next earnings report is expected around September 1, 2026. RNXT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RNXT historically reports after market close (AMC).
RNXT earnings datewhen is RNXT earningsRNXT next earnings datewhen does RNXT report earningsRNXT earnings calendar
▸ Source: FMP · RenovoRx, Inc. SEC filings · US GAAP · RenovoRx, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026